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Using isolated mouse pancreatic lobules, we have previously shown that galanin had no effect on amylase secretion under basal conditions (6) . In the same report, we showed that caerulein, a CCK analog, stimulated amylase secretion in a dose-dependent manner with maximal secretion at a concentration of 10 Ϫ10 M. At higher caerulein concentrations, amylase secretion was reduced. The effect of CCK and caerulein on amylase secretion have been shown to be concentration dependent (30, 34, 43, 46) with variable mechanisms of action depending on the concentrations used, i.e., physiological (10 Ϫ10 M) or supramaximal (10 Ϫ8 M) concentrations (29) . Supramaximal concentrations are used in various animal models of acute pancreatitis (AP), which is exacerbated by galanin and inhibited by galantide (7, 8) .
Exogenous galanin inhibited amylase secretion stimulated by 10 Ϫ10 M caerulein via an insulin-dependent mechanism in our previous studies (6) . The contribution of the pancreatic endocrine system to pancreatic exocrine secretion thus becomes significant in understanding the mechanism underlying the inhibition by galanin of stimulated pancreatic amylase secretion. Henderson (19) had postulated the existence of an islet-exocrine portal system in which the blood from the islets bathes the acinar cells. Subsequent studies have confirmed the importance of islet hormones in the regulation of pancreatic exocrine secretion; although insulin is known to stimulate pancreatic exocrine secretion (31) , somatostatin has been reported to inhibit it (9) .
The role of galanin in AP has been studied in our laboratory using galanin knockout (KO) and wild-type mice (8) . Galanin KO mice were less susceptible to caerulein-induced AP compared with their wild-type littermates. Furthermore, the nonspecific galanin receptor antagonist galantide was found to ameliorate the various indices of AP, including plasma enzyme levels, pancreatic myeloperoxidase activity, and pancreatic histology (8) . One of the possible mechanisms of involvement of galanin in AP, at least in Australian possums, appears to be its effect on pancreatic microvasculature because we found that exogenous galanin reduced pancreatic vascular perfusion (11) . However, the effect of galanin on pancreatic exocrine secretion in the setting of AP has not been previously evaluated. Consequently, to understand the actions of galanin in caeruleininduced animal models of AP, it is necessary to investigate the effect of galanin and its antagonists during supramaximal caerulein stimulation of the exocrine pancreas.
The aim of the present study was to determine the effect of exogenous galanin on amylase secretion from isolated mouse lobules stimulated by supramaximal concentrations of caer-ulein and to clarify the mechanism of galanin of action under these conditions.
MATERIALS AND METHODS
Lobule preparation. These studies were approved by the Flinders University Animal Welfare Committee. Murine pancreatic lobules were prepared as previously described (6) . Briefly, ϳ40 mg wet weight of pancreatic lobule preparation was suspended in 0.5 ml of oxygenated cold modified Krebs solution supplemented with 1.5% dextran and protease inhibitors (Dex-Krebs buffer) and added to each well of a 24-well cell culture plate (Apogent, Roskilde, Denmark). Wells contained varying concentrations of galanin and caerulein (see below). Plates were placed in the airtight containers previously gassed with 5% CO 2-95% O2 and incubated for 60 or 90 min at 37°C in a shaking water bath. Control incubations consisted of lobules incubated in Dex-Krebs buffer alone. To determine whether responses were mediated by nerves or insulin, other experiments were performed in which lobules were preincubated with 1) atropine, a nonspecific muscarinic receptor antagonist (10 Ϫ5 M), 2) tetrodotoxin, a neurotoxin that blocks action potentials by binding to fast voltage-gated sodium channels on nerve cell membranes (10 Ϫ5 M), or 3) diazoxide, which binds K ϩ -ATP channels on ␤ cells of islets to block insulin secretion (10 Ϫ7 M). To confirm that the galanin-evoked responses were mediated by galanin receptors, lobules were preincubated with galantide, a nonspecific galanin receptor antagonist (10 Ϫ7 M) for a further 60 min. To investigate a possible role for somatostatin, lobules were also coincubated with galanin (10 Ϫ12 M), caerulein (10 Ϫ7 M), and octreotide, an octapeptide that mimics somatostatin pharmacologically and is a potent inhibitor of insulin secretion (10
, for 60 min. All incubations were performed in duplicate. The total amylase content of the lobules was determined as previously published (6) .
Carbamoylcholine chloride (carbachol), atropine sulphate, BSA, diazoxide, protease inhibitor cocktail, trypsin-chymotrypsin inhibitor, CAHP, and SDS were purchased from Sigma-Aldrich (St. Louis, MO). Tetrodotoxin was purchased from Alomone Laboratories (Jerusalem, Israel), and galanin (porcine), octreotide, and caerulein were purchased from American Peptide (Sunnyvale, CA). Galantide was purchased from Bachem Bioscience (Bubendorf, Switzerland).
Preliminary experiments were performed to confirm the time course of caerulein. Amylase secretion was linear over a 30 -90-min incubation period, and 60 min was selected for subsequent studies unless otherwise stated. The concentrations of the drugs/peptides used in the various experiments including atropine, tetrodotoxin, and diazoxide were derived from our previous study (6) . Preliminary experiments were also performed to confirm that CAHP acted as a somatostatin inhibitor in the lobule preparation (16, 36) . These studies showed that CAHP (10 Ϫ9 M) antagonized the inhibitory action of octreotide (10 Ϫ7 M) on amylase secretion stimulated by carbachol (10 Ϫ6 M) (data not shown). The amylase activity in the incubation medium (secreted) and in lobules was extracted and assayed as previously described (6) . For graphical presentation, the data are expressed at a percentage of control group amylase activity (lobules incubated in Dex-Krebs only), and the n value refers to the number of preparations.
Statistical methods. Data are presented means Ϯ SE. Statistical analysis was performed using SPSS version 11.5 (SPSS, Chicago, IL). The Mann-Whitney U-test analysis was used for comparison. P Ͻ 0.05 was regarded as statistically significant.
RESULTS
Galanin potentiates supramaximal caerulein-stimulated amylase secretion. We have previously shown that galanin had no effect on basal pancreatic amylase secretion (6) . Amylase secretion from control lobule incubation was 9.5 Ϯ 0.3% of the total amylase content (n ϭ 5). Caerulein at 10 Ϫ7 M stimulated amylase secretion to 124% (11.7 Ϯ 0.4% of total) of control ( Fig. 1) . Coincubation of lobules with galanin increased amylase secretion peaking at about 160% of control (Fig. 1 ).
Galanin at 10
Ϫ12 M produced ϳ50% of the maximal response for galanin, and this was used in subsequent experiments.
Supramaximal caerulein-stimulated amylase secretion: effects of atropine, tetrodotoxin, and diazoxide. Caerulein (10 Ϫ7 M) stimulated amylase secretion to ϳ132% of control in these experiments. Diazoxide (10 Ϫ7 M) preincubation completely abolished the caerulein response (Fig. 2) . Preincubation with tetrodotoxin (10 Ϫ5 M) or atropine (10 Ϫ5 M) significantly inhibited caerulein-stimulated amylase secretion (P Ͻ 0.02) by 47 and 41%, respectively (Fig. 2) . Amylase secretion from control lobules was 12.6 Ϯ 0.2% of total (n ϭ 4).
Potentiation by galanin of supramaximal caerulein-stimulated amylase secretion: effects of atropine, tetrodotoxin, and diazoxide. Caerulein (10 Ϫ7 M) stimulated amylase secretion to 133% of control in these experiments. Coincubation with galanin further stimulated amylase secretion to 183% of control. Pretreatment with diazoxide (10 Ϫ7 M), tetrodotoxin (10 Ϫ5 M), or atropine (10 Ϫ5 M) inhibited the potentiation of galanin by 49 -63% (P Ͻ 0.003; Fig. 3A) . Preincubation of lobules with the combination of atropine (10 Ϫ5 M) and diazoxide Effect of galantide on the galanin potentiation of caeruleinstimulated amylase secretion. The combination of galanin and caerulein stimulated amylase secretion to 184 Ϯ 4% of control in these experiments (n ϭ 4). Preincubation with galantide at 10 Ϫ12 M and 10 Ϫ11 M abolished the galanin-potentiated, caerulein-stimulated amylase secretion, whereas higher concentrations of galantide were less effective; higher concentrations abolished the galanin potentiation but did not prevent a significant increase in amylase secretion (n ϭ 4; P Ͻ 0.05; Fig. 4 ). Amylase secretion from control lobules was 12.08 Ϯ 0.31 of total (n ϭ 4).
Effect of octreotide on caerulein-stimulated amylase secretion.
Caerulein stimulated amylase secretion to 135 Ϯ 2% of control in these experiments (n ϭ 4). Preincubation with octreotide abolished amylase secretion stimulated by caerulein (n ϭ 4; P Ͻ 0.05) (Fig. 5A) . Amylase secretion from control lobules was 11.5 Ϯ 0.32% of total (n ϭ 4).
Effect of octreotide on the galanin potentiation of caeruleinstimulated amylase secretion. The combination of galanin and caerulein stimulated amylase secretion to 153 Ϯ 3% of control in these experiments (n ϭ 4) (Fig. 5B) . Coincubation with octreotide (10 Ϫ11 -10 Ϫ7 M) significantly reduced amylase secretion by 60 -77% of control, and, at 10 Ϫ7 M, the galaninpotentiated, caerulein-stimulated amylase secretion was abolished (n ϭ 4; P Ͻ 0.05) (Fig. 5B) . Amylase secretion from control lobules was 9.3 Ϯ 0.12% of total (n ϭ 4).
Supramaximal caerulein-stimulated amylase secretion: effect of CAHP with and without galanin. In this set of experiments, supramaximal caerulein stimulated amylase secretion to 121% of control, and coincubation with galanin potentiated the amylase secretion to 147 Ϯ 10% of control (n ϭ 4; P Ͻ 0.05). The coincubation of CAHP with supramaximal caerulein increased amylase secretion to 139 Ϯ 5% (P Ͻ 0.05); however, coincubation of CAHP with the combination of supramaximal caerulein and galanin had no additional effect (n ϭ 4; Fig. 6 ). Amylase secretion from control lobules was 9.4 Ϯ 0.3% of total.
DISCUSSION
We have demonstrated for the first time that exogenous galanin potentiates supramaximal caerulein-stimulated amylase secretion from murine pancreatic lobules. Pretreatment with atropine and tetrodotoxin caused a partial inhibition of the amylase secretion induced by supramaximal concentration of caerulein, indicating both neural and nonneural components to this effect (Fig. 7) . The amylase secretion induced by supramaximal caerulein was abolished by pretreatment with diazoxide, implying complete mediation by insulin. The potentiating effect of galanin was abolished by preincubation of lobules with a combination of atropine and diazoxide, supporting muscarinic receptor and insulin mediation. Galantide treatment inhibited the potentiation of galanin, indicating the involvement of galanin receptors. Moreover, administration of octreotide also inhibited the galanin effect, suggesting a role for somatostatin. In support of this, the galanin potentiation was mimicked by pretreatment with CAHP, and CAHP treatment failed to modify the galanin potentiation, suggesting that ga- lanin probably acts by inhibiting the release of somatostatin caused by supramaximal caerulein. On balance, these data suggest that galanin modulates the caerulein-evoked activation of one or more of its receptors located on islet cells and/or via cholinergic nerves to inhibit caerulein-induced somatostatin release.
Regulation of amylase secretion at supramaximal concentrations of caerulein. Pancreatic amylase secretion is under neurohormonal regulation (6) . Previously, we have demonstrated that, in isolated mouse lobules, the caerulein concentration-response relationship was characterized by a peak amylase secretion at 10 Ϫ10 M followed by a fall in amylase secretion at higher concentrations. This phenomenon was noted by Scheele et al. (43) and has been attributed to a number of possible factors, including deranged acinar cell exocytosis. Alternatively, CCK at physiological concentrations may stimulate CCK-A receptors on cholinergic nerves, which innervate the acinar cells to directly induce amylase secretion and innervate islets to release insulin, which also acts on acinar cells to increase amylase secretion (26) . These findings have been confirmed by us in our studies with mouse pancreatic lobules using physiological concentrations of caerulein (6) . However, at higher concentrations of caerulein, the mechanism of stimulation of amylase secretion is more complex. Some investigators believe that, at supramaximal concentrations, CCK acts predominantly on intrapancreatic neurons and acinar cells (34) . Numerous reports have indicated that CCK or caerulein induces amylase secretion from isolated acinar cells, an effect mediated by CCK-A receptors (41, 42) . However, the effect of caerulein at this concentration has been shown to be entirely dependant on insulin (24, 25) . Administration of anti-insulin serum abolished amylase release induced by supramaximal caerulein concentrations. Lee et al. (25) also noted that, in their experiments, the levels of somatostatin had increased in the portal venous effluent and the effect of anti-insulin serum was reversed by the coadministration of anti-somatostatin serum, demonstrating a role for somatostatin. Overall, these findings are consistent with insulin potentiating the effect on CCK/ caerulein acting directly on the acinar cells.
Others believe that a protective mechanism exists whereby, at high local concentrations of CCK, as may be seen after a meal, CCK binds predominantly to CCK-B receptors, which have been shown in mouse to be present on the ␦ cells of the islets and the intrapancreatic neurons (32, 40) . The binding of CCK to the CCK-B receptors on the islets may trigger the release of somatostatin, which leads to the observed reduction in amylase release at supramaximal caerulein concentrations (32, 39) . This action of somatostatin may involve modulation of the interaction of insulin with CCK or a reduction of the binding of CCK to its receptor on the islets cells, namely receptor desensitization or an inhibition of acinar cell basal cAMP formation and a reduction in intracellular Ca ϩ2 signaling stimulated by CCK (17, 28, 36, 39 ). An increase in somatostatin levels in response to CCK and caerulein has previously been reported (21, 22, 37) .
Galanin and supramaximal caerulein-stimulated amylase release. Our previous finding that caerulein-stimulated amylase secretion was greatly reduced by diazoxide and abolished by atropine and tetrodotoxin suggests a dominant role of the neuroendocrine axis, which may involve cholinergic nerves innervating the islets (6; Fig. 7 ). In the present study, the galanin-induced potentiation of the supramaximal caerulein amylase secretion was only inhibited by atropine, tetrodotoxin, or diazoxide; however, it was abolished by the combination of atropine and diazoxide, also implying a neuroendocrine mechanism. To date there has been only one previous study using an isolated and arterially perfused rat pancreas that has shown that galanin enhanced CCK-stimulated amylase secretion, and this was associated with increases in insulin concentration (38) . Because somatostatin release was not measured in this study, a possible role for this islet hormone was not considered. Our data with galantide, a nonspecific galanin receptor antagonist (12, 27) , supports galanin acting via one or more galanin receptors.
Somatostatin and its effect on the galanin potentiation. Somatostatin is known to inhibit amylase release. The possible mechanisms underlying the inhibition of somatostatin of CCK/ caerulein-stimulated amylase secretion include inhibition of insulin release and thus a reduction in the stimulatory effect of insulin (24, 25, 28) , inhibition of acetylcholine release from nerve terminals that express specific somatostatin receptors (18) , and a reduction in the intracellular cAMP (33, 35) , thereby reducing Ca ϩ2 signaling in acinar cells directly affecting the secretory response of the acinar cells (44) . Somatostatin has also been shown to inhibit the excitatory effect of neuronal activation on CCK-induced pancreatic secretion (35) .
We demonstrated that coincubation with the somatostatin analog octreotide resulted in a significant reduction in the galanin-induced potentiation of the supramaximal caerulein amylase secretion. This raised the possibility that the potentiating action of galanin may involve suppression of somatostatin release. Galanin has been shown to inhibit somatostatin release (4, 10) . We found that preincubation with CAHP mimicked the effect of galanin on supramaximal caeruleinstimulated amylase secretion. The lack of further action on coincubation of CAHP with galanin and supramaximal caerulein is consistent with the potentiating effect of galanin being attributable to its inhibition of endogenous somatostatin release evoked by supramaximal caerulein (Fig. 7) . The exact source of endogenous galanin is unclear. The available evidence, which includes the demonstration of galanin immunoreactivity in relation to nerves innervating the islets (2, 5, 13) , suggests that nerves (most likely sympathetic) (14) and islets are potential sources for endogenous galanin although extrapancreatic sources cannot be ruled out (3).
In conclusion, our data suggest that caerulein stimulates amylase secretion by a predominantly neuroendocrine mechanism. At supramaximal caerulein concentrations, galanin via its receptors further increases caerulein-stimulated amylase secretion by inhibiting the release of somatostatin caused by high caerulein.
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